Organization (Industry)
Endocyte (United States)
ClinicalTrials.gov lists Endocyte (United States) as lead sponsor of 29 trials. It has 15 active development programs and 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Endocyte (United States): 29 lead-sponsored trials and 1 legal-entity registration.
Disease areas (27)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Ovarian Neoplasms | 8 |
| Neoplasm Metastasis | 5 |
| Prostatic Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Lung Neoplasms | 4 |
Showing 5 of 27 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2020 | 2 |
| 2018 | 3 |
| 2017 | 2 |
| 2014 | 3 |
| 2013 | 2 |
| 2012 | 1 |
| 2011 | 2 |
| 2010 | 1 |
| 2009 | 2 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (15)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| 177Lu-PSMA-617 | Prostatic Neoplasms | Phase 3 | 1 |
| Tc 99m EC20 | Ovarian Neoplasms | Phase 2 | 3 |
| Tc 99m EC20 | Endometrial Neoplasms | Phase 2 | 2 |
| Tc 99m EC20 | Head and Neck Neoplasms | Phase 2 | 1 |
| Tc 99m EC20 | Neoplasm Metastasis | Phase 2 | 1 |
Showing 5 of 15 active programs.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| 177Lu-PSMA-617 | 2 |
| Interleukin 2 | 2 |
| DOCETAXEL | 1 |
| Folic (or folinic) acid | 1 |
| CARBOPLATIN | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 4 hit target (n=4) | 0 of 3 on time (n=3) |
Journals published in (23)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Lancet. Oncology | 7 |
| European urology | 3 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2 |
| Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 1 |
Showing 5 of 23 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 60 | 10 | 2025-11-18 |
Latest dated events (95)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-04-08 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-03-04 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-01-28 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-12-31 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 95 events.
Biomarker capability evidence (83)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| BRCA1 | Trial sponsor | Named in trial inclusion criteria |
| CSF2 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 83 evidence rows.
On Scientist.com
Endocyte (United States) is listed as a research supplier in the Scientist.com network.
Although great progress has been made in the development of new drugs to treat cancer and other serious illnesses, it is still difficult to predict if a patient will respond positively to existing therapies. In addition, therapies are often administered at suboptimal doses because of their effects on healthy tissues.
Addressing these challenges through precision medicine has been our mission since the very beginning. Physicians aspire to treat patients with precision medicine, and Endocyte is committed to giving them the tools to do it.
- Website
- endocyte.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Endocyte on Scientist.com
For prices, more details, or to contact Endocyte, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.